{
}
Pharma giants are experiencing a slowdown in earnings growth, primarily due to their reliance on the US generics market and a lack of major drug launches. Companies like Cipla, Dr Reddy's, and Aurobindo Pharma face challenges from rising competition and impending patent expirations, while midcap firms focused on the domestic market continue to thrive without the same pressures.
Spiriva
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
pharma sector faces growth slowdown while domestic market thrives
United States Dollar
Aurobindo Pharma Limited
SBI Life Insurance Company Ltd.
Cipla Limited
DR Reddy'S Laboratoire Ltd.
TVS Motor Company Limited
HUL
Lupin Limited
IND
Lupin
Spiriva
Cipla
Dr Reddy's
Aurobindo Pharma
Show more
05:31 25.10.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
Global Trade Developments
Stock Market Updates
Industry Mergers & Acquisitions
Private Equity Deals
Supply Chain Management
Government Economic Policies
Retail and Consumer Goods
Fintech Startups
Venture Capital Investments
Inflation and Monetary Impact
CEO Changes
Finance Mergers & Acquisitions
AI Innovations
Workplace Trends
Energy Sector Developments
Economic Indicators
Central Bank Actions
Countries:
Companies:
Apple Inc.
Google Inc.
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
NIO Inc.
Nikkei 225
Delhivery Limited
Ecom Express Ltd.
Nintendo Co., Ltd.
Microsoft Corporation
Eurasia Groupe SA
British International Investment plc
XPeng Inc.
Li Auto Inc.
Morgan Stanley
Taiwan Semiconductor Manufacturing Company Limited
VFS Global AG
LARGAN Precision Co.,Ltd
S&P/ASX 200
HANG SENG BANK
Currencies:
United States Dollar
Indian Rupee
Euro
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
South Korean Won
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Offshore Chinese Yuan
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
Thai Baht
Mexican Peso
Croatian Kuna
Bahraini Dinar
Egyptian Pound
People: